[Businesswire]

。Demonstrated strong safety and favorable pharmacokinetics in Phase 1 study

。A First-in-class oral small molecule modulating immune cell metabolism via glycogen phosphorylase inhibition

。Once-daily oral administration with high patient convenience

。Broad development potential in ulcerative colitis and other autoimmune diseases

☞ Article link